Leishmania major: histopathological responses before and after topical treatment in experimental animals.
The cellular response in the cutaneous leishmaniasis lesion (CL), of BALB/c mice treated topically with an ointment composed of 15% paromomycin and 12% methylbenzethonium chloride (PR-ointment) was studied. In the infected, untreated control group, the lesion showed progressive necrosis with an increase in the number of parasites, macrophages, lymphocytes, and polymorphonuclear cells over a period of 18 weeks. In the PR ointment-treated group, complete healing of the lesion was observed 4 weeks after termination of treatment, but total elimination of the parasites from the lesion was observed only 2 weeks later. A marked reduction in the number of macrophages and polymorphonuclear cells was observed during the healing process. A similar phenomenon was observed with mice inoculated intraperitoneally with paromomycin alone, although total elimination of the parasites from the lesions of these mice was not demonstrated over a period of 18 weeks. Neither L3T4 helper T cells nor Ly2 cytotoxic suppressor T cells were detected in the CL lesion, either before or after treatment.
El-On
J
J
Department of Microbiology and Immunology, Faculty of Health Sciences, Beer Sheva, Israel.
Lang
E
E
Kuperman
O
O
Avinoach
I
I
D000287:Administration, Topical; D000818:Animals; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000627:therapeutic use*; D001558:Benzethonium / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*; D003094:Collagen / Q000032:analysis; D004338:Drug Combinations; D005260:Female; D007895:Leishmania tropica; D007896:Leishmaniasis / Q000188:drug therapy* / Q000469:parasitology / Q000473:pathology; D008214:Lymphocytes; D008264:Macrophages; D008407:Mast Cells; D051379:Mice; D008807:Mice, Inbred BALB C; D009504:Neutrophils; D009824:Ointments; D010303:Paromomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D000644:Quaternary Ammonium Compounds / Q000627:therapeutic use*; D012867:Skin / Q000469:parasitology / Q000473:pathology
D000891:Anti-Infective Agents, Local; D004338:Drug Combinations; D009824:Ointments; D000644:Quaternary Ammonium Compounds; D001558:Benzethonium; D010303:Paromomycin; D003094:Collagen; C005106:methylbenzethonium chloride